Research Ethics and Financial Disclosure

Maintaining a stringent regulatory oversight of financial interests and disclosures is pivotal in clinical research ethical standards. The public well-being is always at stake when a new product is in the market. Ultimately, the primary objective of a regulatory agency’s purview on financial disclosure requirements’ is to protect the best interest of human subjects while negotiating the best possible common grounds that meets a safe introduction of new medicinal product in the marketplace. Under the International Conference on Harmonization (ICH) guidelines, all the regulatory agencies worldwide, requires provisional financial disclosures to the sponsor company from the principal investigators (PIs), research institutions, etc. involved in conducting the clinical trials (ICH, 1997). Financial disclosure is a necessary tool in clinical trials when the efforts in innovation focus on obtaining statistical and clinical significance of a medicinal product. Also, financial disclosure processes and evaluations are multi-faceted with ethical concerns. Thus, financial disclosure or

This content is restricted to site members. If you are an existing user, please login. New users may register below.

Existing Users Log In